Literature DB >> 27176752

Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies.

Anders Lykkemark Simonsen, Pia Brandt Danborg, Peter Christian Gøtzsche.   

Abstract

BACKGROUND: Sexual dysfunction is a common adverse effect of selective serotonin reuptake inhibitors (SSRIs) and there is a concern that the sexual harms might persist after discontinuation of therapy.
OBJECTIVE: To assess whether the use of SSRIs in animals can lead to persistent sexual dysfunction.
METHODS: Systematic review of animal studies measuring sexual behaviour after end of treatment with SSRIs or serotonin norepinephrine reuptake inhibitors. DATA SOURCES: We searched PubMed and EMBASE.
RESULTS: We included 14 studies. The general quality of the studies was poor. Only four studies reported use of randomisation and none mentioned allocation concealment. All studies used placebo and were therefore blinded. For rats exposed to SSRIs compared with those exposed to placebo, we found a higher risk of no mounting behaviour (RR = 0.73; 95% CI = 0.62-0.86), no intromission behaviour (RR = 0.74; 95% CI = 0.60-0.92) and no ejaculation behaviour (RR = 0.49, 95% CI = 0.24-1.00).
CONCLUSION: Our results showed substantial and lasting effects on sexual behaviour in rats after exposure to an SSRI early in life on important sexual outcomes.

Entities:  

Keywords:  Selective serotonin reuptake inhibitors (SSRIs); animal studies; long lasting harm; permanent sexual dysfunction; systematic review

Mesh:

Substances:

Year:  2016        PMID: 27176752     DOI: 10.3233/JRS-160668

Source DB:  PubMed          Journal:  Int J Risk Saf Med        ISSN: 0924-6479


  4 in total

Review 1.  [Sexual dysfunction associated with psychotropic drugs and treatment options].

Authors:  M Berner
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

2.  Citizen petition: Sexual side effects of SSRIs and SNRIs.

Authors:  David Healy
Journal:  Int J Risk Saf Med       Date:  2018

3.  Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin.

Authors:  David Healy; Audrey Bahrick; Maarten Bak; Angelo Barbato; Rocco Salvatore Calabrò; Barbara M Chubak; Fiammetta Cosci; Antonei B Csoka; Barbara D'Avanzo; Silvia Diviccaro; Silvia Giatti; Irwin Goldstein; Heiko Graf; Wayne J G Hellstrom; Michael S Irwig; Emmanuele A Jannini; Paddy K C Janssen; Mohit Khera; Manoj Therayil Kumar; Joanna Le Noury; Michał Lew-Starowicz; David E J Linden; Celine Lüning; Dee Mangin; Roberto Cosimo Melcangi; Omar Walid Muquebil Ali Al Shaban Rodríguez; Jalesh N Panicker; Arianna Patacchini; Amy M Pearlman; Caroline F Pukall; Sanjana Raj; Yacov Reisman; Rachel S Rubin; Rudy Schreiber; Stuart Shipko; Barbora Vašečková; Ahad Waraich
Journal:  Int J Risk Saf Med       Date:  2022

4.  Persistent adverse effects of antidepressants.

Authors:  Joanna Moncrieff
Journal:  Epidemiol Psychiatr Sci       Date:  2019-09-23       Impact factor: 6.892

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.